Free Trial

Fresenius Medical (FMEGR: Baa3/BBB-/BBB- Neg) 2Q Results

HEALTHCARE

(Healthcare); results look like a slight miss on headline but EBIT coming in-line. FY outlook affirmed and looks like consensus already there,

  • Revenue at €4.8b (-1%), EBIT €0.43m (+21%) at 8.9% margin (+150bps).
  • FCF €0.29b, net debt reduced to €10.7b which it says is net 3.1x and "lower end of self-imposed target corridor"
  • Outlook affirmed for LSD to MSD revenue growth and EBIT growth in mid to high teens (c+14%). Also affirms EBIT margin target of 10-14% "by 2025".

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.